Effectiveness of high cost systemic treatments in malignancy
Research type
Research Study
Full title
Effectiveness of systemic treatments in poor prognosis malignancy in routine care. An analysis of outcomes in England using the SACT database.\n\nShort title: Systemic treatments in poor-prognosis malignancy\n
IRAS ID
262026
Contact name
David Dodwell
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
6 years, 0 months, 0 days
Research summary
To study survival outcomes in well-defined large cohorts of patients receiving CDF [cancer drug fund supported] or other drugs with a clearly defined place in therapy for poor prognosis cancer.\nTo compare survival outcomes with those seen in registration level RCTs and other prospective clinical trials.\nTo use data within SACT (chemotherapy database) but also those linked to multiple other NCRAS datasets to define patient characteristics that may influence survival and other outcomes.\nTo study population-level variability in uptake of cancer drugs according to geography, socio-economic status and provider trust.\n\nTo study and develop indicators of significant toxicity including early [<30 day] mortality & hospital admissions\n\nTo help inform clinical information provision and decision making by providing a better understanding of outcomes in routine care.\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
19/NS/0057
Date of REC Opinion
11 Apr 2019
REC opinion
Favourable Opinion